In humans, pharmacological modulation of the ERN1 protein can counteract metaflammation (ubiquitous low levels of inflammation throughout the body) a process that is associated with blood vessel–affecting diseases such as atherosclerosis, chronic heart disease, and diabetes mellitus [34]. Here, ERN1 is linked to diabetes mellitus.